Dentsply Sirona enters five-year partnership agreement with Smile Train » 07:3909/2409/24/21
Dentsply Sirona is…
Dentsply Sirona is launching this partnership with Smile Train to improve oral health globally and to build a brighter, more sustainable future for children and families affected by cleft worldwide. We are going beyond traditional financial and equipment donations. The Dentsply Sirona and Smile Train partnership will advance the future of cleft care by: Supporting global treatment standards and best practices for digitized cleft care; Leveraging digital technologies to make treatments more efficient and convenient for children; Providing high quality equipment to develop state-of-the-art centers for cleft treatment; Making our entire online catalog of clinical education courses available to all Smile Train oral health professionals; and Offering financial support for cleft surgeries. The company is focused on making sure the benefits of our Smile Train partnership have a lasting impact. Therefore, in addition to funding life-changing cleft surgeries and providing free dental equipment, the collaboration focuses on global, oral healthcare training initiatives to equip people in local communities with the skills needed to provide treatment and raise the standard of care to the highest level through Clinical Education and the use of cutting-edge technologies in the long term. Additionally, the partnership includes the development of an International Smile Train Scholars program, which will support in-person and virtual training and learning opportunities for Smile Train dental partners. A group of 16 scholars are attending DS World 2021, participating in clinical education sessions and growing their professional networks.
Tandem Diabetes price target raised to $135 from $123 at SVB Leerink » 07:2909/2409/24/21
SVB Leerink analyst…
SVB Leerink analyst Danielle Antalffy raised the firm's price target on Tandem Diabetes to $135 from $123 and keeps a Market Perform rating on the shares. While Antalffy believes the insulin pump market will continue to grow strong double-digits, and Tandem Diabetes will also continue to grow, the analyst is somewhat skeptical that the company can continue to drive the extent of sales upside over the mid to long-term that it has seen over the last several years, she tells investors in a research note.
Harpoon Therapeutics CFO buys 10.3K shares of common stock » 08:1409/2309/23/21
In a regulatory filing,…
In a regulatory filing, Harpoon Therapeutics disclosed that its CFO Georgia Erbez bought 10.3K shares of common stock on September 22nd in a total transaction size of $83.4K, boosting her stake by about 12%. Shares of Harpoon Therapeutics are up about 4% in pre-market trading at $8.42.
Dentsply Sirona announces new sustainability strategy » 07:4109/2309/23/21
Dentsply Sirona announced…
Dentsply Sirona announced its updated sustainability strategy, the release of its inaugural sustainability report, and new sustainability hub on its website. Dentsply Sirona's disclosure is aligned with the guidelines from the Sustainability Accounting Standards Board and the Task Force for Climate-related Financial Disclosures. "Dentsply Sirona's sustainability strategy focuses on three strategic pillars: 'Healthy Planet,' which strives to mitigate the environmental impact of our operations; 'Healthy Smiles,' which focuses on improving oral health quality and access globally, supporting our customers and fostering a healthy company culture; and, 'Healthy Business,' which ensures our business is built via responsible and transparent practices and the effective integration of sustainability principles across all aspects of our business," the company said. 2020 sustainability highlights and the next milestones: "Healthy Planet" highlights: established a robust baseline for Scopes 1 and 2 greenhouse gas emissions, and implemented a range of on-site emissions reduction initiatives; set out to reduce Scopes 1 and 2 GHG Emissions Reduction more than or equal 15% by 2025, and to achieve net zero carbon emissions by 2050; 6% YOY decrease in total waste per measure of net sales, and set out to reduce total waste more or equal than 15% by 2025; and established a goal to reduce water withdrawal for manufacturing/warehouse operations by more or equal to 15% by 2025. "Healthy Smiles" highlights: trained more than 1M dental professionals in 2020; nearly 7,300 Clinical Education and training courses conducted in 80 countries; set goal to achieve 25 million smiles by 2025; working to achieve gender parity and gender pay parity by 2025; and more than $10M provided in cash and in-kind donations to philanthropic and community initiatives. "Healthy Business" highlights: 50% of Board members are gender and/or ethnically diverse, with average tenure of 5 years; 60% of Board committees chaired by women; and 91% of Board is independent.
SVB Leerink to hold a virtual event » 04:5509/2309/23/21
AVRO, CRNX, INSM, MREO, ORTX, RPHM, SPRB, TALS
Neuromuscular, Rare Diseases & Genetic Medicines Virtual Event to be held on September 22-23.
Axonics Medtronic provides update on inter partes review proceedings » 18:1409/2209/22/21
Axonics (AXNX) announced…
Axonics (AXNX) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic (MDT) patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review to contest the validity of patents Medtronic has alleged to be infringed by Axonics. In September 2020, the PTAB granted Axonics' request and instituted a review of the six Medtronic patents. On September 13, 2021, the PTAB issued its decision with respect to Patent Nos. 7,774,069; 8,626,314, and 8,036,756. Today, the PTAB issued its decision on the three remaining Medtronic patents Axonics is contesting: Patent Nos. 9,821,112 ('112 patent), 8,457,758 ('758 patent); and 8,738,148 ('148 patent). Either party may appeal the IPR decisions to the Director of the Patent & Trademark Office and to the U.S. Court of Appeals for the Federal Circuit. Axonics expects the stay on legal proceedings in the U.S. District Court in the Central District of California to continue until the appeals process is complete. "First and foremost, it is important to understand that the PTAB rulings as to whether the claims in the Medtronic patents are valid or not do not mean that anyone has 'won' anything. When one party suggests that another party is infringing, the other party often asks the PTAB to determine if the claims in the patents are actually valid. This is what Axonics has done and for Medtronic to claim 'victory' is purely posturing. The fact that the PTAB decided to invalidate several claims in Medtronic's '112 patent is a net positive for Axonics. Moreover, we believe the PTAB's narrow construction of the claims in the '758 patent and '148 patent strengthens our non-infringement argument. Axonics remains confident that it does not infringe any Medtronic patents - valid or invalid - and that we will ultimately prevail on the patent claims asserted against us," said Raymond Cohen, CEO of Axonics.
Neurocrine initiated with a Hold at Needham » 16:2609/2209/22/21
Needham analyst Ami Fadia…
Needham analyst Ami Fadia initiated coverage of Neurocrine with a Hold rating. The company has 4 late-stage programs, but the Street is unlikely to give much credit for these as data readouts for most are not likely before 2023, the analyst tells investors in a research note. Faida adds that while Neurocrine will have 7 Phase 2 trials underway by year-end FY21, adding longer-term growth drivers, the stock is unlikely to reflect these until more data becomes available, which is "not likely anytime soon".
Intra-Cellular initiated with a Buy at Needham » 16:2409/2209/22/21
Needham analyst Ami Fadia…
Needham analyst Ami Fadia initiated coverage of Intra-Cellular with a Buy rating and $55 price target. The analyst believes Caplyta's growth is underappreciate and that there is pipeline upside. Fadia anticipates Caplyta will gain approval for bipolar disorder depression at the December 17, 2021 PDUFA and projects sales quickly growing to $435M in 2024 and $775M in 2026.
Ideaya Biosciences initiated with a Hold at Stifel » 16:1609/2209/22/21
Stifel analyst Benjamin…
Stifel analyst Benjamin Burnett initiated coverage of Ideaya Biosciences with a Hold rating and $27 price target. The analyst said that while he resonates with the synthetic lethality approach, he worries that clinical data for lead SL program IDE397 will come in below expectations.
Icon awarded EUR4M R&D support contract in Ireland » 16:0809/2209/22/21
The Tanaiste and Minister…
The Tanaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD announced htat ICON plc has been awarded EUR4M in R&D support administered by Enterprise Ireland to further enhance its data solutions and decentralised clinical trial technology. The COVID-19 pandemic has accelerated the clinical research industry's move to hybrid and decentralised trials, requiring researchers and regulatory bodies to adapt to the ways participants live their connected and mobile lives. As the most advanced healthcare intelligence and clinical research organisation in the industry, ICON will utilise the funding to further invest in the build-out of its world-class technology and data solutions architecture. The support will promote broad clinical research participation while also delivering real-time access to data, higher levels of security, and improved timelines and reduced costs for customers.